Fulcrum Therapeutics (FULC) Cash from Financing Activities (2018 - 2026)
Fulcrum Therapeutics (FULC) has 9 years of Cash from Financing Activities data on record, last reported at -$312000.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities changed N/A to -$312000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $168.4 million, a 15274.89% increase, with the full-year FY2025 number at $168.7 million, up 6042.28% from a year prior.
- Cash from Financing Activities reached -$312000.0 in Q1 2026 per FULC's latest filing, down from $168.3 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for FULC hit a ceiling of $168.3 million in Q4 2025 and a floor of -$312000.0 in Q1 2026.
- A 5-year average of $24.9 million and a median of $348000.0 in 2022 define the central range for Cash from Financing Activities.
- Peak YoY movement for Cash from Financing Activities: crashed 99.27% in 2022, then surged 202673.49% in 2025.
- Tracing FULC's Cash from Financing Activities over 5 years: stood at $218000.0 in 2022, then skyrocketed by 31.65% to $287000.0 in 2023, then crashed by 71.08% to $83000.0 in 2024, then soared by 202673.49% to $168.3 million in 2025, then tumbled by 100.19% to -$312000.0 in 2026.
- Business Quant data shows Cash from Financing Activities for FULC at -$312000.0 in Q1 2026, $168.3 million in Q4 2025, and $64000.0 in Q3 2025.